VBI Vaccines Inc.
12
1
1
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
16.7%
2 terminated/withdrawn out of 12 trials
80.0%
-6.5% vs industry average
42%
5 trials in Phase 3/4
88%
7 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
Role: lead
Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection
Role: collaborator
Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a
Role: lead
PREHEVBRIO Pregnancy Outcomes Registry
Role: lead
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901e With E6020 Adjuvant
Role: lead
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a
Role: lead
A Bridging Study: Comparing Two Lots of Sci-B-Vac™ and Engerix-B in Healthy Adults
Role: lead
Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® Compared to Engerix-B®
Role: lead
A Study to Qualify an In-house Reference Standard Batch of Sci-B-Vac™
Role: lead
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
Role: lead
Immunogenicity and Safety of Sci-B-Vac® to Engerix-B® in Adults
Role: lead
Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults
Role: lead
All 12 trials loaded